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ABSTRACT 
 
 
Background: Orphan diseases are defined as any disease, syndrome, or disorder 
that affects less than 200,000 persons in the United States. Most of these 
disorders are genetic in origin. However, with so few patients to study, 
researchers have struggled to collect enough data on any one orphan disease to 
make progress towards treatment and/or a cure. But, with the recent monumental 
advances in the field of genetic sequencing techniques, there has been an 
explosion in the potential avenues of study for these scientists. We hope to use 
data generated from whole exome studies of our orphan disease patients to 
identify potential disease-causing genetic lesions, and therefore solve the 
mystery of the genetic basis of their condition. 
Methods: For each family enrolled in our study, genomic DNA samples from the 
proband and his/her mother and father were evaluated for whole exome 
sequencing (performed by Axeq Technologies). We sorted and filtered these 
results using a variety of parameters until discovering a genetic variant we 
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believed to potentially explain the phenotype of each patient. Once a gene of 
interest was identified, we used Sanger sequencing to confirm the mutation. At 
the present moment, we are at a variety of stages of progress amongst our study 
of our different patients. For our patients thought to be affected by dysfunctional 
SPEG, we have been working on a SPEG-CKO mouse model in attempt to 
recreate the phenotype we see in our patients and further study the function of 
SPEG. For our patient thought to be affected by dysfunctional PHKG1 and our 
patient thought to be affected by dysfunctional LAMA1, we are in the process of 
studying whether their mutations affect the expression and/or function of the 
associated proteins.  
Results: While we are still developing our mouse colonies, we have successfully 
developed a SPEG-CKO mouse model. With respect to PHKG1, we are still 
searching for another mutation, for both the proband and father are heterozygous 
for the same frameshift mutation, but only the proband is clinically affected. Our 
studies of LAMA1 appear promising, for the patient carries two mutations which 
segregate to each parent. However, more data must be collected on the 
expression of this protein, particularly with respect to whether it could cause the 
pontocerebellar hypoplasia phenotype. 
Conclusion: While major challenges still remain for orphan disease research, we 
will continue our investigations in hopes of determining the genetic basis of 
disease in these marginalized patients. 
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INTRODUCTION 
 
Orphan Diseases 
Orphan diseases are defined by the Orphan Drug Act of 1983 as any 
disease, syndrome, or disorder that affects less than 200,000 persons in the 
United States (Hudson & Breckenridge, 2012). Presently, there are over 6,000 
rare or orphan diseases, many of which are genetic in origin (Holtzclaw Williams, 
2011). A few examples of orphan disease can be found in Table 1.  
 
 
Table 1: Examples of Orphan Diseases. Estimated prevalence data as 
reported by Orphanet, November 2012 (“Orphanet Report Series - Prevalence of 
rare diseases: Bibliographic data,” 2012). 
 
 
Disease Prevalence (/100,000) Age of Onset 
Inheritance 
Pattern 
Associated 
Gene(s) 
Noonan 
Syndrome 50 Neonatal/Infancy 
Autosomal 
Dominant 9 
Lennox-Gastaut 
Syndrome 15 Childhood Sporadic 2 
Moyamoya 
Disease 3.16 Variable 
Autosomal 
Recessive, 
Sporadic, 
Autosomal 
Dominant 
2 
Albers-
Schönberg 
Osteopetrosis 
1 Childhood Autosomal Dominant 1 
Van den Bosch 
Syndrome 1 family No data available 
X-Linked 
Recessive 0 
Rudiger 
Syndrome 2 cases Neonatal/Infancy 
Autosomal 
Recessive 0 
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As can be seen above, many orphan diseases manifest during childhood. 
Unfortunately, as many as 30% of affected children die before the age of five 
(Azie & Vincent, 2012). Until recently, the technology and funding have not been 
available to make considerable progress in understanding these rare diseases. 
However, with the advent of next-generation sequencing (NGS) technologies and 
increased funding grants specifically targeted to research on rare diseases, 
breakthroughs are being made in our understanding of orphan diseases. With 
this new technology, we are beginning to discover the associated genes mutated 
in these patients, therefore allowing us to piece together genotype-phenotype 
correlations.  
 
Next-Generation Sequencing 
 Since the completion of the Human Genome Project in 2003, a revolution 
has occurred in the field of genetics research. As such, advances in sequencing 
methods were also in need of tremendous improvement to keep pace. 
Historically, researchers have been using the Sanger sequencing method since it 
was developed in 1975 (Pareek, Smoczynski, & Tretyn, 2011). The Sanger 
method employs a variety of techniques: bacterial cloning or polymerase chain 
reaction (PCR), template purification, labeling of deoxyribonucleic acid (DNA) 
fragments using the chain termination method, dye-labeling dideoxynucleotides 
and DNA polymerase, capillary electrophoresis, and fluorescence detection 
(Metzker, 2010). While the Sanger method has been a remarkable tool in 
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genetics research, it is limited in the amount of data it can generate and the 
speed and cost at which it can do so.  
 Next-generation sequencing (NGS) technologies are the latest innovation 
in genetics and genomics research, capable of generating over 100 times more 
data than that compared to the Sanger method (Pareek et al., 2011). The first 
NGS system appeared on the market in 2005, and since then, NGS technologies 
have been providing innumerable opportunities for genome-wide studies with 
their ability to sequence billions of bases in a single run (Pareek et al., 2011). 
 Genome-wide studies are particularly important in the context of orphan 
diseases, for in many cases, we have no hypothesis as to the genetic cause. 
Therefore, by screening a patient’s entire genome (in the present study we just 
focused on the coding parts of the genome – the exome), we are given direction 
as to which genes are mutated, and therefore might be causing the disease. 
 
Background on Select Orphan Disease Patients 
2190 and 3025: Centronuclear Myopathy 
Centronuclear myopathies (CNM) are a heterogeneous group of rare 
inherited muscle disorders. The most distinguishing histopathological finding of 
CNM is the presence of large numbers of myofibers with centrally placed nuclei, 
hence the name. The disease generally presents early in life with relatively non-
progressive weakness and hypotonia. The complete clinical picture, however, is 
highly variable depending on the mode of inheritance and the causative mutation. 
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There are three forms of inheritance of CNM: autosomal dominant (AD), 
autosomal recessive (AR), and X-linked recessive (also known as X-linked 
myotubular myopathy or XLMTM). In general, the X-linked form is the most 
severe, the AD form is the mildest, and the AR form follows an intermediate 
course (Jungbluth, Wallgren-Pettersson, & Laporte, 2008). The most severe 
phenotype (XLMTM) is exhibited at or soon after birth, presenting with globalized 
muscle weakness and respiratory failure (Pierson, Tomczak, Agrawal, 
Moghadaszadeh, & Beggs, 2005). In addition, affected infants present with 
length >90th percentile, large head circumference (70% of cases), 
narrow/elongated face (80%), and slender, long digits (60%) (Joseph, Pai, 
Holden, & Herman, 1995). Unfortunately, most of these patients do not survive 
past infancy or early childhood. One study reviewed 84 patients with XLMTM and 
found a 74% mortality rate in the first month of life and 10% additional deaths 
within the first year of life (De Angelis, Palmucci, Leone, & Doriguzzi, 1991). 
To date, mutations in myotubularin (MTM1), dynamin 2 (DNM2), 
amphiphysin 2 (BIN1), and ryanodine receptor 1 (RYR1) are known to cause 
CNM (Bitoun et al., 2005; Catteruccia et al., 2013; Laporte et al., 1996; Lee et al., 
2013; Nicot et al., 2007; Wilmshurst et al., 2010). However, the genetic basis for 
20-40% of CNM cases is still unknown. Patients 2190 and 3025 are two such 
cases. 
The first patient (2190), a full term female infant born to consanguineous 
parents of Turkish descent, died on day 22 of life due to severe muscle 
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weakness. A muscle biopsy showed a marked increase in myofibers with central 
nuclei (Figure 1A) and the presence of a few necklace fibers (Figure 1B). She 
was diagnosed with myotubular myopathy. 
The second patient (3025) is a six-year-old female who has a 
tracheostomy, is dependent on mechanical ventilation, and has gastrostomy with 
fundoplication. Her histopathological findings included small myofiber size and 
marked increased number of central nuclei (Figure 1C). She was also diagnosed 
with myotubular myopathy in addition to dilated cardiomyopathy and congestive 
cardiac failure.  
 
 
 
 
 
 
 
 
 
 
Figure 1: Muscle Biopsy Findings in Patients 2190 and 3025. Findings 
include an increase in central nuclei (arrows) on hematoxylin and eosin (H&E) 
staining in patients 2190 (1A) and 3025 (1C) and the presence of necklace fibers 
(arrow heads) on NADH staining in 2190 (1B). 
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146-1: Cardiomyopathy and Glycogen Metabolism Disorder 
Cardiomyopathy refers to diseases of heart muscle that manifest with 
different types of structural and functional phenotypes. There are several 
classifications of cardiomyopathies: dilated cardiomyopathy (DCM), hypertrophic 
cardiomyopathy (HCM), restrictive cardiomyopathy (RCM), arrhythmogenic right 
ventricular cardiomyopathy/dysplasia (ARVC/D), and unclassified 
cardiomyopathies (Cooper, 2013). 
Glycogen is the storage form of glucose that is broken down in times of 
energy demand. Glucose and glycogen metabolism require an elaborate 
interplay of enzymes involved in synthesis, degradation, and regulation of various 
compounds. There are many inborn errors of glucose and glycogen metabolism 
that result from mutations in these enzymes. The clinical manifestation of the 
metabolic disorder will depend on the importance of the nonfunctional/altered 
enzyme, but can include hypoglycemia, muscle symptoms (muscle pain, cramps, 
weakness, etc.), and hepatomegaly (Craigen & Darras, 2013). 
One of our enrolled patients, 146-1, was a female infant with marked 
cardiomegaly, extreme concentric four-chamber hypertrophy, and other findings 
consistent with HCM. In addition to her cardiac phenotype, she displayed a 
glycogen metabolism disorder with severe lactic acidosis. She died at the age of 
24 days. 
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199-1: Pontocerebellar Hypoplasia 
Pontocerebellar hypoplasia (PCH) encompasses a group of prenatal-
onset neurodegenerative disorders. There are several different subtypes, but all 
share the common presentation of: hypoplasia/atrophy of the cerebellum and 
pons, progressive microcephaly, and the potential for greater cerebral 
involvement (Namavar, Barth, Poll-The, & Baas, 2011). Clinical differences 
between the subtypes can be found in Table 2, while differences in pathological 
findings can be found in Figure 2. 
Patient 199-1 enrolled in our study with the diagnosis of PCH. She is a 
one-year old female born of Indian descent who presented at birth with 
arthrogryposis, microcephaly, micrognathia, upslanting palebral fissures, small 
mouth with high-arched and narrow palate, feeding dyscoordination, myoclonic 
seizures, and multiple skeletal anomalies. In addition, MRI revealed diffuse 
cerebral and cerebellar parenchymal volume loss as well as decreased caliber of 
brain stem, consistent with pontocerebellar hypoplasia. 
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Table 2: Subtypes of Pontocerebellar Hypoplasia. Table compiled with data 
from Maricich et al. and Namavar et al. (Maricich et al., 2011; Namavar et al., 
2011) 
 
 
PCH 
subtype 
Distinguishing 
Findings 
Causative 
Gene/Locus 
Gene 
Product 
PCH1A VRK1 Serine-threonine kinase 
PCH1B 
Hypotonia, impaired 
swallowing, congential 
contractures and/or 
polyhydramnios, primary 
hypoventilation, progressive 
microcephaly 
EXOSC3 Ribosomal RNA-processing protein 
PCH2A TSEN54 
PCH2B TSEN2 
PCH2C 
Clonus, impaired swallowing, 
chorea, variable spastic 
pareses, progressive 
microcephaly, severe 
cognitive and motor 
development  TSEN34 
tRNA splicing 
endonucleases 
PCH3 
Brachycephaly, wide-set 
eyes, hyperreflexia, seizures, 
optic atrophy, deafness 
Locus on 
chromosome 
7 q 
? 
PCH4 
Dysmorphism, hyperekplexia, 
seizures, myoclonus, infantile 
encephalopathy 
TSEN54 tRNA splicing endonuclease 
PCH5 
Hyperreflexia, hypertonia, 
camptodactyly, contractures, 
micrognathia 
TSEN54 tRNA splicing endonuclease 
PCH6 Encephalopathy, hypotonia, apnea, seizures RARS2 
Mitochondrial 
arginyl-tRNA 
synthetase 
PCH7 
Regression of penis, 
progressive microcephaly, 
seizures, respiratory distress, 
poor feeding 
No locus ? 
PCH8 
Severe psychomotor 
retardation, abnormal 
movements, hypotonia, 
spasticity, variable visual 
defects 
CHMP1A Chromatin-modifying protein 
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Figure 2: Magnetic Resonance Imaging (MRI) Sections of PCH Patients. 
Images from a 2-week-old neonate with PCH1 are displayed in 2A-C. 
Pathological findings include vermal hypoplasia and marked cerebellar 
hypoplasia (2A-B) in addition to flattened cerebellar hemispheres exhibiting 
some atrophy (2C). Images of a 2-month-old baby with PCH2 are displayed in 
2D-E. Findings in this patient include a flat ventral pons, vermal hypoplasia (2D) 
and severely hypoplastic cerebellar hemispheres (arrow, 2E). 2F shows a 
coronal section of a 9-month-old infant, also with PCH2. This patient displays 
dragonfly configuration – flat cerebellar hemispheres and mild vermal hypoplasia. 
Images from a 31+5 week neonate with PCH4 are found in 2G-I. Findings include 
severe vermal hypoplasia, ventral pontine flattening (2G), severe cerebellar 
hypoplasia, increased distance between cortical surface and skull (2H), and 
immaturity of the cerebral cortex with enlarged ventricles (2I). (Image reproduced 
from Namavar et al., 2011.) 
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Genes of Interest 
Striated Preferentially Expressed Gene  
We decided to investigate striated preferentially expressed gene (SPEG) 
further in patients 2190 and 3025 after reviewing the whole exome results and 
because the dilated cardiomyopathy found in patient 3025 was similar to the 
phenotype found in the knock out mouse model for SPEG (SPEG-KO) described 
by our collaborator’s team (Liu et al., 2009). 
SPEG is a member of the Myosin Light Chain Kinase (MLCK) family. The 
MLCK family is a group of proteins that are important for myocyte function, 
including structure and regulation of the actin-based cytoskeleton. Through 
alternative promoter use and splicing in a tissue-specific manner, four different 
isoforms can be generated: SPEGα, SPEGβ (both preferentially expressed in 
cardiac and skeletal muscles), aortic PEG (APEG), and brain PEG (BPEG) (Liu 
et al., 2009).  
Little is known about the function of SPEG except for Liu and colleagues’ 
recent study. They created a SPEG-KO mouse model by removing exons 8, 9, 
and 10 of the SPEG locus. The resulting mutant phenotype was dilated 
cardiomyopathy. 
 
Phosphorylase Kinase, Gamma Subunit 1 
From results generated from whole exome study on patient 146-1, we 
decided to focus on PHKG1 as a gene of interest, for lactic acidosis can be a 
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presentation of glycogen storage disease and PHKG1 plays an important 
regulatory role in glycogenolysis (Sever, Weinstein, Wolfsdorf, Gedik, & 
Schaefer, 2012).  
PHKG1 is the muscle isoform of phosphorylase kinase gamma subunit. 
Phosphorylase kinase (Phk) is a 16-subunit protein complex that contains 
equimolar ratios of four subunit types: alpha, beta, gamma, and delta (Vénien-
Bryan et al., 2009). The complex is an important regulator of glycogenolysis for it 
stimulates glycogen breakdown by phosphorylating (activating) glycogen 
phosphorylase (Burwinkel et al., 2003).  
Approximately 25% of all glycogen storage diseases can be accounted for 
by Phk deficiency. Previously, mutations in the muscle isoform of the Phk alpha 
subunit (PHKA1) were found to cause low activity of muscle Phk, but none have 
been found in PHKG1 (Burwinkel et al., 2003). 
 
Laminin, Alpha Subunit 1 
From results generated from whole exome study on patient 199-1 and the 
correlation between cerebellar development and laminin as demonstrated by 
laminin-KO mouse models (Heng et al., 2011; Ichikawa-Tomikawa et al., 2012), 
we decided to focus on LAMA1 as a gene of interest. LAMA1 is a basement 
membrane protein that is essential for embryonic development.  
Conditional knockout mouse models for LAMA1 have shown that 
deficiency of LAMA1 results in disorganization and volume loss of the cerebellum 
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(Heng et al., 2011; Ichikawa-Tomikawa et al., 2012). However, no known 
mutations in LAMA1 have been shown to cause pontocerebllar hypoplasia in 
humans. 
 
Prior Research to Present Study 
Through our collaboration with Liu et al., (2009) we obtained slides 
containing skeletal muscle tissue from a pair of SPEG/APEG KO mice and the 
littermate control (Figure 3). Our analysis of these slides has revealed an 
increased number of central nuclei (mean of 6.5% versus 2.5%) and reduced 
mean diameter of the myofibers (9.6 mm versus 11.9 mm) (Figure 4). 
 
 
 
 
Figure 3: Hematoxylin and Eosin Staining of Skeletal Muscle Tissue From 
Wildtype (WT) and SPEG/APEG KO Mice. Myofibers containing central nuclei 
(arrows) are increased in the SPEG/APEG KO mice. 
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Figure 4: Smaller Fiber Size and Increase in Central Nuclei in SPEG/APEG 
KO Mice. The bar diagram shows that the mean fiber size is smaller and number 
of fibers containing central nuclei is increased in the KO mice. 
 
 
In addition to the mutant phenotype of dilated cardiomyopathy, smaller 
fiber size, and increase in central nuclei, the SPEG/APEG KO mice exhibited 
significant neonatal mortality by day 2 (Liu et al., 2009). To decrease neonatal 
mortality, we aimed to create a conditional KO model by excising exons 14-17. In 
this manner, SPEG is removed but not APEG. This is an important distinction, for 
APEG plays a critical role in embryonic vascular development, while SPEG is not 
expressed until after birth.  
 
Specific Aims of Present Study 
As discussed, orphan diseases have not received much attention in the 
past. However, now that we are able to generate enormous amounts of data 
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based on the sequencing of a patient’s genome, researchers are now given 
starting points at which to focus their studies. 
This study aims to investigate the genetic causes of a host of orphan 
diseases. While rare, understanding these unusual disease processes may lead 
to broader scientific implications for overall human health. More specifically we 
aim to: 
(1) Screen orphan disease patients for disease-causing mutations 
through whole exome sequencing analysis. 
(2) Confirm mutations that have been reported to us by whole exome 
sequencing. 
(3) Evaluate genotype-phenotype correlations between genes that are 
affected and the clinical findings of each patient. 
(4) Develop a conditional knock out mouse model for SPEG. 
(5) Evaluate PHKG1 expression and function in 146-1. 
(6) Evaluate LAMA1 expression and function in 199-1. 
 
We hope these studies will more fully explain the genetic basis of select 
orphan diseases as well as suggest potential avenues for treatment of these rare 
disorders. 
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METHODS 
 
Participant Eligibility and Enrollment 
 Under IRB Protocol #10-02-0053, patients in the Neonatal Intensive Care 
Unit (NICU) at Boston Children’s Hospital with an orphan disease or an 
unclassified rare disorder were eligible and offered participation in the present 
study. Other family members, primarily the biological parents of each enrolled 
patient, were also invited to participate. 
 
Medical and Family History 
 Each family completed medical questionnaires that included questions on 
age, ethnic background, pregnancy history, and health status/history. A pedigree 
was created for each family enrolled and, through permission granted from 
medical record release forms, we obtained each patient’s medical records, 
including results from previous clinical and genetic tests and any pathology 
reports that were pertinent to our research. 
 
Blood, Saliva, and Tissue Sample Collection 
 Each child and his/her parents were asked to give a blood sample from 
which we isolated DNA. Alternatively, if we were unable to obtain a blood 
sample, we collected a saliva sample or cheek swab of cells. Additionally, tissue 
samples were asked of certain individuals enrolled in the study. Tissue was 
 16 
either obtained from a previous biopsy, another medically indicated 
procedure/surgery, or an autopsy study. 
 
Whole Exome Sequencing by Axeq Technologies 
 One microgram of genomic DNA from each proband, his/her mother, and 
his/her father were prepared as a sequencing library through a series of steps. 
First, the genomic DNA was fragmented by nebulization (procedure that 
generated double-stranded DNA fragments of less than 800 base pairs 
comprised of 3’ or 5’ overhangs), followed by repair (converted overhangs into 
blunt ends), ligation of an ‘A’ to the 3’ end (prepared ends for ligation to adapters 
which have a single ‘T’ base overhang at their 3’ end), and ligation of specific 
adapters to the fragments (allowed for hybridization in future steps). Next, the 
ligation products were run on a gel and products sized 350-400 base pairs were 
selected and amplified using PCR. 
 Once the DNA library was created, it was mixed with capture probes for 
target regions (genes of interest). This step is referred to as the first 
hybridization. The DNA library was then washed three times to remove any non-
specific binding. Next, the library was mixed with capture probes of targeted 
regions for a second hybridization, ensuring further enrichment of targeted 
regions. Three wash steps, once again, removed any non-specific binding. PCR 
was then used to amplify the enriched DNA library for sequencing. 
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The enriched captured libraries were then sequenced using Illumina 
HiSeq 2000 Sequencer.  
 
Sequencing Data Analysis and Variant Filtering 
Once the sequencing was complete, the results were mapped against 
UCSC hg19 (http://genome.ucsc.edu/) as the reference genome. SAMtools 
(http://samtools.sourceforge.net/) was then used to detect any single-nucleotide 
polymorphisms (SNPs) and insertions/deletions (Indels) that were present in 
each individual. The detected variants (SNPs and Indels) were then filtered 
against the databases Single Nucleotide Polymorphism database (dbSNP) 
(http://www.ncbi.nlm.nih.gov/projects/SNP/) and 1000 Genomes 
(http://www.1000genomes.org/), both of which archive the frequency of variants 
found in the human population. 
 
Exploration of Variants in Context of Patient Phenotype 
 Once we received the sequencing data analysis report from Axeq 
Technologies, we sorted the variants using a variety of parameters. First, we 
filtered out any SNPs or Indels that were located in an untranslated region (UTR) 
or in an intron, for these changes most likely would not cause significant change 
to the encoded protein. Next, we investigated the remaining exonic SNPs (coding 
mutations) for ones that were synonymous amino acid changes versus 
nonsynonymous changes, for we are only interested in the nonsynonymous 
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SNPs. Nonsynonymous SNPs are of particular interest, for amino acid 
substitutions account for the majority of known human disease-causing genetic 
lesions (Ng & Henikoff, 2003). 
Of the remaining variants, we researched the genes in which these 
variants were present. Comparing patient phenotype with gene function, we 
aimed to find genes that if impaired or nonfunctional might cause the patient’s 
clinical symptoms.  
 
Prediction of Variant Significance 
 As we sorted through the various genetic variants, we also evaluated each 
variant’s prediction scores of disease-causing potential. Two programs generated 
prediction values: Polymorphism Phenotyping version 2 (PolyPhen-2) and 
Sorting Intolerant From Tolerant (SIFT). 
PolyPhen-2 is a tool that predicts the consequences of an amino acid 
substitution on the structure and function of a protein using multiple alignments of 
homologous sequences and three-dimensional structural features (Adzhubei et 
al., 2010). Higher PolyPhen scores indicate an increased likelihood of that amino 
acid substitution causing damage to the protein. 
SIFT predicts whether an amino acid substitution has the potential to 
affect protein function based on the principles of conservation – the more highly 
conserved an amino acid is amongst species, the more important that amino acid 
is for protein function (Ng & Henikoff, 2003). Therefore, amino acid substitutions 
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at highly-conserved positions are predicted to be the most damaging. SIFT 
scores less than 0.05 are considered deleterious. 
 
Variant Confirmation 
 Potential genetic variants of interest were confirmed with Sanger 
sequencing to ensure their presence in the patient’s genomic DNA. Sanger 
sequencing is a widely used method with a standard protocol (Sanger, Nicklen, & 
Coulson, 1977). 
 
Further Molecular Studies on SPEG 
Generation of SPEG Conditional Knock Out (SPEG-CKO) Mice 
To better understand the function of SPEG, we have created a conditional 
knockout mouse. The targeting strategy is described in Figure 5. The Speg-CKO 
mice are currently being bred with Zona pellucida 3 Cre-expressing mice (ZP3-
Cre) to create constitutive Speg-KO mice. This work is still in progress. 
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Figure 5: Targeting Strategy for SPEG-Conditional KO Mice. A 11.5 kb region 
used to construct the targeting vector was first sub cloned from a positively 
identified C57BL/6 (RP23: 305K9) BAC clone. The region was designed such 
that the short homology arm (SA) extends ~2.3kb 5’ to exon 14. The long 
homology arm (LA) ends 3’ to exon 17 and is 7.5kb long. The loxP/FRT flanked 
Neo cassette is inserted on the 5’ side of exon 14 and the single loxP site is 
inserted between exons 17-18. The target region is 1.76kb and includes exons 
14-17.   
 
Further Molecular Studies on PHKG1 
mRNA Extraction from Heart Tissue 
 For patient 146-1, we received a heart tissue sample from which we 
decided to extract mRNA in efforts to determine whether there was differential 
expression of the patient’s two alleles.  
To extract mRNA from the tissue, we excised a small sample weighing 
less than 30 mg. We placed the tissue in a round-bottomed tube and added 300 
µL of Buffer RLT. Using a TissueRupture, we disrupted and homogenized the 
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tissue sample until we achieved a uniformly homogenous lysate. We then added 
590 µL of RNase-free water to the lysate, followed by 10 µL of proteinase K 
solution. We mixed this solution thoroughly by pipetting. Next, we incubated the 
solution at 55°C for 10 minutes and centrifuged at 20-25°C for 3 minutes at 
10,000 x g. A small pellet of tissue debris formed. We pipetted the supernatant 
(approximately 900 µL) into a new 1.5 mL microcentrifuge tube. Then we added 
0.5 volumes of ethanol to the cleared lysate and mixed well by pipetting. We 
transferred 700 µL of the sample to an RNeasy Mini spin column placed in a 2 
mL collection tube. After closing the lid gently, we centrifuged the sample at 20-
25°C for 15 seconds at >8,000 x g. The flow-through was discarded. We then 
transferred the remainder of the sample to the RNeasy Mini spin column and 
centrifuged the sample at 20-25°C for 15 seconds at >8,000 x g. The flow-
through was again discarded. Next, to wash the membrane, we added 350 µL of 
Buffer RW1 to the RNeasy spin column, closed the lid gently, and centrifuged the 
sample at 20-25°C for 15 seconds at >8,000 x g. The flow-through was 
discarded. 
Next we made a DNase I incubation mix by adding 10 µL of DNase I stock 
solution to 70 µL Buffer RDD. We added 80 µL of this incubation mix directly to 
the RNeasy spin column membrane and left on the benchtop (20-30°C) for 15 
minutes. Afterwards we added 350 µL of Buffer RW1 to the RNeasy spin column, 
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closed the lid gently, centrifuged for 15 seconds at >8,000 x g at 20-25°C, and 
discarded the flow-through. Next we washed the membrane by adding 500 µL of 
Buffer RPE to the RNeasy spin column, closing the lid gently, centrifuging for 15 
seconds at >8,000 x g at 20-25°C, and discarding the flow-through. We washed 
the membrane once more by adding 500 µL of Buffer RPE to the RNeasy spin 
column, closing the lid gently, centrifuging for 2 minutes at >8,000 x g at 20-
25°C, and discarding the flow-through. To finish and elute the RNA, we placed 
the RNeasy spin column in a new 1.5 mL collection tube, added 30 µL of RNase-
free water directly to the spin column membrane, closed the lid, and centrifuged 
at >8,000 x g at 20-25°C for 1 minute. The RNA was then ready to be converted 
to cDNA. 
 
Conversion of mRNA to cDNA 
 In a 0.5 mL tube, we combined the extracted mRNA, primers, and a dNTP 
mix and incubated the solution at 65°C for five minutes followed by placing it on 
ice for at least one minute. Next we prepared a cDNA synthesis mix that 
contained 10X RT buffer, 25 mM MgCl2, 0.1 M DTT, RNaseOUT™, and 
SuperScript™ III RT. We then added 10 µL of this cDNA synthesis mix to the 
RNA/primer mixture, gently mixed, collected by brief centrifugation, and 
incubated for 10 minutes at 25°C followed by 50 minutes at 50°C. We then 
terminated the reaction at 85°C for 5 minutes and chilled on ice. We collected the 
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reaction by brief centrifugation, added 1 µL of RNase H to the tube, and 
incubated for 20 minutes at 37°C. The cDNA was then stored at -20°C until it was 
needed for PCR. 
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RESULTS 
 
Whole Exome Sequencing: Results and Analysis 
 The first step in our analysis was to filter out all mutations except for Indels 
and SNPs that were coding (exonic) and SNPs that created nonsynonymous 
changes (coded for a different amino acid than the reference genome). Table 3 
displays this preliminary filtering. Note the large number of potential disease-
causing mutations that still remained. 
 
Table 3: Preliminary Variant Filtering. Below are the summary results reported 
to us by Axeq Technologies. We sequenced genomic DNA of the probands 
(2190, 3025, 146-1, 199-1) and their mothers (146-2, 199-2) and fathers (146-3, 
199-3). Synonymous refers to a base change that does not affect the amino acid 
it codes for and nonsynonymous refers to a base change that causes an amino 
acid substitution. 
 
 
 
 
Individual Number of SNPs 
Number 
of coding 
SNPs 
Number of 
synonymous 
SNPs 
Number of 
non-
synonymous 
SNPs 
Number 
of Indels 
Number 
of 
coding 
Indels 
2190 63,953 18,521 N/A N/A 12,717 449 
3025 66,490 19,232 N/A N/A 12,917 465 
146-1 85,382 23,643 12,383 10,681 8,536 385 
146-2 87,801 24,079 12,690 10,835 8,888 418 
146-3 86,165 23,395 12,237 10,569 8,799 409 
199-1 77,528 20,847 10,772 9,555 7,966 413 
199-2 79,101 21,816 11,351 9,905 8,191 442 
199-3 76,626 20,745 10,777 9,470 7,759 422 
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Whole Exome Sequencing: Variants of Interest 
Of the coding nonsynonymous SNPs and coding Indels, we looked to see 
if any occurred in genes that might play a role in the patient’s phenotype. Table 4 
lists the mutations we find of particular interest to each patient. 
 
Table 4: Variants of Interest. Variant locations (chromosome and base 
number), base changes (reference compared to patient’s alternative), and 
resulting amino acid (aa) changes. 
 
 
Individual Chr Pos Gene Ref  base 
Alt  
base Ref aa Alt aa 
2190 chr02 220348882 SPEG C T Q Stop gain 
chr02 220338454 SPEG C T R Stop gain 
3025 
chr02 220333976 SPEG - 
Del 36 
bp 
T Frameshift 
146-1 chr07 56149341 PHKG1 - Ins C S Frameshift 
chr18 6943284 LAMA1 C T R C 
199-1 
chr18 7080084 LAMA1 C T R C 
 
 
SPEG 
Patients 2190 and 3025 were identified as carrying SPEG mutations. 2190 
was identified to carry a homozygous SPEG mutation, c.C6697T postulated to 
cause a stop gain (p.Q2233X) change (Figure 6). 3025 was compound 
heterozygous for a stop gain (c.C4276T; p.R1426X) mutation (Figure 7, top). 
Additionally, through Sanger sequencing all the SPEG exons, we discovered a 
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36 base pair (bp) deletion in exon 13 that caused a frameshift mutation 
(c.3709_3715+29del36; p.T1237Sfs*46) (Figure 7, bottom).
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Generation of SPEG-CKO Mice 
We have successfully created SPEG-CKO mice (Figure 8). 
 
 
 
 
 
 
 
 
 
 
Figure 8: SPEG-CKO Mice Genotyping Results. PCR results of genotyping 
using tail DNA. The SPEG-CKO shows a larger band than WT due to the 
addition of the 63 bp loxP cassette. 100 bp ladder was used as reference.  
 
 
PHKG1 
Patient 146-1 was found to carry a PHKG1 mutation, c.900_901insC, 
causing a frameshift mutation (p.S300fs). This mutation was also found in the 
proband’s father (Figure 9). 
 In addition, we extracted mRNA from the proband’s heart tissue sample in 
order to evaluate the allelic expression of PHKG1. We found both alleles (normal 
and mutant) to be expressed equally (Figure 10). 
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LAMA1 
Patient 199-1 was found to carry two LAMA1 mutations, which segregate 
appropriately to her parents (Figures 11 and 12). Both mutations are missense 
mutations that cause an arginine to be substituted for a cysteine. The first 
mutation (c.8962C>T, p.R2988C) is present in the proband and her mother. The 
second mutation (c.235C>T, p.R79C) is present in the proband and her father. 
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DISCUSSION 
 
 This study has provided some preliminary insights into potential genetic 
causes of select orphan diseases. We are at various stages of progress in 
identifying the genetic basis of disease in each patient. 
 
Analysis of Results and Future Studies 
SPEG-KO Mouse Model 
Now that we have created a conditional KO model, we will breed these 
mice with a ZP3-Cre expressing line to constitutively remove SPEG, as 
previously described by our team for the gene cofilin-2 (Agrawal, Joshi, Savic, 
Chen, & Beggs, 2012). Once we have created these constitutive KOs, we hope 
to evaluate the phenotypes, understand the disease mechanisms, and explore 
their utility as potential models for future therapeutic trials. 
We aim to further study the phenotype of these mice through 
histopathological studies of skeletal muscles and assessment of overall muscle 
performance and contractility.  
 
SPEG Human Patients 
We expect to obtain muscle biopsy samples from patients 2190 and 3025. 
The muscle biopsies will be utilized for histopathological, biochemical, and 
physiological studies to better understand the pathophysiology of these 
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conditions. The planned experiments on these biopsies include Western blot 
analysis to evaluate protein amounts using anti-SPEG antibodies. These future 
studies will be important for identification of appropriate subgroups of patients for 
future therapeutic trials. 
Additionally, we will continue to screen CNM and various other myopathy 
patients from our database and those of several international muscle research 
teams for SPEG mutations, continuing to search for genotype-phenotype 
correlations that may exist. 
 
PHKG1 and LAMA1 Human Patients 
We will continue to search for an additional genetic variant in PHKG1 in 
patient 146-1, for the one frameshift mutation we have found does not suffice 
alone to cause disease due to the fact that the proband’s father carries the same 
mutation and is unaffected. We hypothesized that there may be some other 
mutation in the proband that caused silencing of the normal allele, leaving only 
the mutant allele to be expressed. However, after extracting mRNA and 
converting it to cDNA to be sequenced, we found both alleles (normal and 
mutant) to be present. For the future, we will perform a Western blot with an anti-
PHKG1 antibody in hopes of finding decreased expression of PHKG1 in the 
proband. This finding could suggest the presence of a mutation hiding 
somewhere upstream of the gene that is affecting the transcription or translation 
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of the protein, and therefore lend more credence to the theory that a mutated 
PHKG1 is causing the disease. 
For 199-1, we feel LAMA1 is a promising genetic culprit. However, more 
studies need to be done to elucidate the functional consequences of these 
mutations. Is the protein expression decreased or is the protein dysfunctional in 
some respect? Is the protein expressed in the cerebellum of human patients and 
could lack/dysfunction of this protein cause pontocerebellar hypoplasia? While 
we believe to have a starting point to focus our studies, more research must be 
done to be confident that mutations in LAMA1 are causing the disease. 
 
Implications for Therapy and Policy 
 Along with defining the criteria for a disease to be considered an orphan 
disease, The Orphan Drug Act of 1983 provided incentives for pharmaceutical 
companies to develop drugs, biotechnology products, and medical devices for 
treatment of these disease despite the small market for them (Holtzclaw 
Williams, 2011). These incentives included: assistance in developing the 
necessary protocols for preclinical and clinical studies for market approval, 
waiver of marketing application fee, grants, and seven-year marketing exclusivity 
(Griggs et al., 2009). However, the drug industry did not adequately fund the 
research needed to develop these “orphan drugs” (Holtzclaw Williams, 2011). 
 Though that is not to say that no progress has been made. One of the first 
companies to take advantage of the incentives offered by The Orphan Drug Act 
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was Genzyme Corporation in 1991 in their development of alglucerase 
(Ceredase) to treat Gaucher disease (Griggs et al., 2009).  
Challenges certainly still remain for funding research into drugs for these 
marginalized orphan disease populations and for controlling the high cost of drug 
development for such a small market, but with the increased efficiency and 
decreased associated costs of NGS technologies, we hope more laboratories will 
have the ability to perform this necessary and important research. 
 
Psychosocial Implications 
 A review performed by Cohen & Biesecker (2010) investigated the factors 
that contribute to quality of life in patients with rare genetic conditions. They 
found that in addition to the physical symptoms of patient’s disease, 
psychological health, coping, and illness perceptions also play a role in a 
patient’s quality of life (Cohen & Biesecker, 2010). This finding suggests the need 
for a “new frontier” in rare disease research (Holtzclaw Williams, 2011). We will 
need to look past developing cures for physical manifestations of disease and 
begin to formulate interventions aimed at addressing the non-physical burdens 
these patients experience. The Health Disparity Research and Education Act of 
2000 and the Genetic Information Nondiscrimination Act of 2008 were developed 
to bring attention to such issues (Holtzclaw Williams, 2011). It will certainly be 
interesting to see how the scientific and greater health care fields respond to the 
needs presented in these acts. 
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Conclusion 
 In summary, orphan disease research is a fascinating and understudied 
field. We will continue to build upon our investigations in hopes of one day being 
able to put a family’s worries at ease with the knowledge of understanding the 
genetic basis of their child’s rare disease. 
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